NCT06786624
Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 21 words
- Trial sites expanded: 18 → 30 locations
- Interventions modified
- Study title revised
- Minor Study sites: 6 to 18v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 6
- Start date changed from estimate of Jan 2025 to Jan 22, 2025
- Notable Primary and study completion dates: Nov 2026 to Jul 2027v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56
Timeframe: Baseline, Day 56
Secondary (2)
Change from Baseline in Sheehan Disability Scale (SDS) Total Score at Day 56
Change from Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score at Day 56
Arms and interventions
OsavampatorExperimental
Osavampator administered orally once a day.
PlaceboPlacebo comparator
Placebo identical in appearance to osavampator will be administered orally once a day.
Drugs: Osavampator, Placebo
Sites
30 sites in 4 countries
United States 18, Czechia 5, Poland 5, Croatia 2